we conducted a randomized study comparing the survival after treatment with cisplatin ( 120 mg/m2 ) or cisplatin plus etoposide ( 100 mg/m2 on days 1 , 2 , and 3 ) in 162 evaluable patients with advanced non-small-cell lung cancer ( nsclc ) .
C0008838
cisplatin
C0078414
cisplatin